Vir Biotechnology 1 article

The durable scientific profile of Vir Biotechnology centers on immune-based therapeutics, with hepatitis B immune therapy forming a complementary therapeutic or mechanistic axis. Vir Biotechnology combines hepatitis D therapeutics, monoclonal antibody antiviral discovery and T-cell engager infectious disease research, giving Vir Biotechnology an explicit target or pathway context. Vir Biotechnology is therefore matched through a combination of mechanisms including pathogen-specific immune targeting, while individual products remain independently tagged.